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Abstract
Background: In order to optimally integrate the use of high-throughput sequencing (HTS) as a tool in clinical
diagnostics of likely monogenic disorders, we have created a multidisciplinary “Genome Clinic Task Force” at the
University Hospitals of Geneva, which is composed of clinical and molecular geneticists, bioinformaticians,
technicians, bioethicists, and a coordinator.
Methods and results: We have implemented whole exome sequencing (WES) with subsequent targeted
bioinformatics analysis of gene lists for specific disorders. Clinical cases of heterogeneous Mendelian disorders
that could potentially benefit from HTS are presented and discussed during the sessions of the task force.
Debate concerning the interpretation of identified variants and the content of the final report constitutes a
major part of the task force’s work. Furthermore, issues related to bioethics, genetic counseling, quality control, and
reimbursement are also addressed.
Conclusions: This multidisciplinary task force has enabled us to create a platform for regular exchanges between all
involved experts in order to deal with the multiple complex issues related to HTS in clinical practice and to
continuously improve the diagnostic use of HTS. In addition, this task force was instrumental to formally
approve the reimbursement of HTS for molecular diagnosis of Mendelian disorders in Switzerland.
Background
Since the technological and bioinformatics developments
of high-throughput sequencing (HTS) and the use of ex-
ome sequencing for the discovery of new genes causative
of Mendelian disorders [1, 2], this technology has been
rapidly and widely integrated in the clinical setting [3] as
it outperforms previously used methods in diagnostic
yield, time, and cost-effectiveness [4]. However, the use of
HTS technology in the clinical setting brings its own set
of challenges (7), although many of them were already
encountered during the introduction of other genomic
diagnostic methods such as array CGH. The main
challenges of diagnostic HTS include pre- and post-
HTS counseling with appropriate and adapted in-
formed consent [5, 6], bioinformatics analysis setup
and validation [7], variant interpretation and classifi-
cation [8–10], specific policies concerning the identifi-
cation and disclosure of variants not directly linked
to the patient’s phenotype [11], validation of HTS as
a diagnostic test that conforms to quality control
standards [12], data storage and accessibility, and re-
imbursement issues [13], as well as updates and
follow-up strategies. In order to optimally integrate
HTS into the clinical practice and to continuously
improve this novel and rapidly evolving diagnostic ap-
proach, we have realized quite early in the process
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the need for a multidisciplinary approach. Accordingly,
the Genome Clinic Task Force (GCTF) was established
in 2012, with the specific objective to provide a plat-
form for regular exchanges of all involved specialists
in order to find solutions for the various types of
problems and concerns that we may encounter by
performing HTS in our clinic. Currently, this task
force meets once per week and is composed of
roughly 25 specialists and a coordinator, including
clinical geneticists (consultants and trainees), molecu-
lar biologists, scientists, bioinformaticians, bioethicists,
and technicians (Fig. 1).
In this review, we present the composition, practices,
and workflow of the GCTF, the results obtained to
date, the challenges we have encountered, the reim-
bursement directives that were officially introduced in
Switzerland in January 2015 by the Swiss Federal Office of
Public Health (SFOPH), and the lessons learned from this
experience.
The Genome Clinic Task Force (GCTF) of the
University Hospitals of Geneva
Figure 1 shows the organization of the GCTF working
group as well as the tasks that the two sections (clinical
and laboratory) have to fulfill. The head of our Genetics
Institute, an MD, PhD, is the director of the task force.
The coordinator is a trained PhD molecular biologist
with experience in health policy and diagnostic issues.
The role of the coordinator is to perform the prepara-
tory work of each GCTF session, to formalize the proce-
dures, to record the minutes of all GCTF sessions, and
to handle relevant administrative tasks. The clinical sec-
tion consists of the clinical geneticists of our service,
who present patients to the task force and critically
examine the indications of HTS for each patient, as well
as providing their input regarding the clinical interpret-
ation of identified variants. The HTS laboratory section
is headed by a senior molecular biologist with appropri-
ate qualifications for molecular diagnostic services and
subdivided in a sequencing, bioinformatics, and analysis
groups. Finally, two bioethicists from the Institute of
Bioethics of the University of Geneva are participating in
the weekly meetings. Their participation helps to imme-
diately address ethical issues that may arise during the
discussions. The profession of the genetic counselor (as
it is defined in the USA) is not formally recognized as
such in Switzerland, and thus genetic counselors are not
included in the task force.
Standard operating procedure
The different steps of the diagnostic workflow are
shown in Fig. 2 and illustrated by an example. This
standard operating procedure was among the initial
objectives of the GCTF and is regularly reviewed ac-
cording to the evolution of this diagnostic field. As mi-
nutes of all GCTF meetings are written, all discussions
and decisions taken can be referred to and reevaluated
according to new experiences, international recom-
mendations, and practical considerations. As shown in
the flowchart, every case that undergoes diagnostic
HTS is discussed at least three times in the GCTF: a
first time before the test is performed (step 2), a second
time during the preliminary report (step 7), and a third
time (step 8) during the presentation and debate of the
final report. The following paragraphs provide more de-
tails on the operating procedure.
Pre-test considerations (steps 1, 2, and 3 of Fig. 2)
Clinical cases that have been seen for genetic counseling
at the Genome Clinic (step 1) and who may benefit from
HTS are presented by one of the clinical geneticists at
the GCTF (step 2) in order to evaluate within the task
force the clinical and reimbursement aspects of the case
and to decide whether the patient is appropriate for a
HTS approach. In general, we accept patients who suffer
from a likely heterogeneous Mendelian disorder with at
least one known clearly pathogenic gene or patients with
a developmental delay of unknown origin. The cost of
the HTS analysis has to be less than that of Sanger se-
quencing for the corresponding genes. Physicians from
other medical specialties may also present their cases
during the sessions. These presentations include a de-
tailed family history, personal medical history, photos if
available, genetic tests that have already been performed,
and the list of genes proposed to be tested. So far, 246
patients have been presented to the GCTF and 240 cases
were accepted. Two were redirected towards research
projects due to the absence of clearly known pathogenic
genes causing their respective phenotypes, while two
other cases were rejected because their phenotypes were
multifactorial with genetic predispositions identified
through GWAS studies but without a known monogenic
cause. One case was not accepted because a specific
Fig. 1 Organization chart of the Genome Clinic Task Force
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standard genetic test was judged more appropriate than
HTS, and another case was rejected because it consisted
of a prenatal diagnosis based on ultrasound findings
without a specific hypothesis for a Mendelian disorder.
Once a case is accepted for HTS, the GCTF mem-
bers discuss and define the most appropriate targeted
gene panel. Since we use exome sequencing followed
by bioinformatics selection of genes of interest, the
clinical geneticists continuously reevaluate and update
the gene lists. Before a gene panel is created or reeval-
uated, a detailed research of the literature is performed
for recent review papers and available proposed gene
panels (academic and commercial). Frequently used
gene lists, such as the intellectual disability panel, are
reviewed biannually or sooner at the request of the re-
ferring physician, while rarely used lists are reevaluated
each time they are needed. As illustrated by the ex-
ample, we initially used rather restrictive gene panels
in order to minimize the incidental findings. In cases
where no pathogenic variant was identified, we had the
tendency to add a second or even a third bioinformat-
ics analysis using additional genes. This multi-step ap-
proach was eventually deemed time consuming. Thus,
we have recently decided to directly include all poten-
tially causative genes in the panels.
After the pre-test GCTF decision, the patients or the
legal representative are seen for a pre-HTS genetic con-
sultation by one of the clinical geneticists (step 3). The
patients are informed about the procedure and the pos-
sible results, including incidental findings in case of large
panels. If they agree to be tested, we discuss and explain
the specific HTS informed consent form, which we have
developed in collaboration with the Swiss Society of
Medical Genetics (ww.sgmg.ch) and with the input of
the bioethicists. The patients can opt-in for the following
categories of incidental findings, which are available only
for the specific set of genes that will be analyzed:
1. Disorders for which no medical intervention
(curative or preventive) is possible
2. Disorders for which medical intervention (curative
or preventive) is possible
3. Carrier status for recessive disorders.
HTS and bioinformatics analysis (steps 4, 5, and 6 of Fig. 2)
One important decision was the choice of the HTS
strategy [14]. The different options included (i) WES
and analysis of all genes implicated in Mendelian disor-
ders; (ii) WES and bioinformatics targeted analysis of
gene lists; (iii) targeted gene panels only, and (iv) whole
genome sequencing (WGS) and bioinformatics targeted
analysis of gene lists. Based on the previous experience
from research projects [15, 16], we have chosen to
perform whole exome sequencing (WES) followed by
targeted analysis of specific sets of genes. Trio exome
sequencing (patient and parents) was not considered
due to limitations imposed by the Swiss medical insur-
ance reimbursement regulations.
Exome capture is performed using the SureSelect
Human ALL Exon technology (Agilent Technologies,
Santa Clara, CA, USA), and the sequencing is realized
in an Illumina HiSeq 2000 instrument (usually 100 bp
paired-end, Illumina, San Diego, CA, USA). Read map-
ping, variant calling, and variant annotation are performed
using a locally developed bioinformatics tool that surveys
the sequential progress of the data from BWA [14] for
Fig. 2 Overview of the practical steps (1–9) of the Genome Clinic Task Force
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mapping (hg19) and Samtools [15] and Pindel [16] for
SNV and indel calling. Targeted bioinformatics analysis of
the selected genes of interest is performed through locally
developed pipelines, which select only the variants from
the specified genes of interest, masking the rest of the
data. We have validated the sequencing and variant detec-
tion quality by sequencing DNA samples from the individ-
ual for which sets of high-quality variants are publicly
available (Platinum Genomes, Illumina®) and obtained
99.6 % concordance for the SNVs and 97.8 % for the
indels. The bioinformaticians from the HTS section follow
the updates of the databases (Table 1). New versions are
implemented 1 to 3 months after they become publicly
available. Software updates (Table 1) follow a more
lengthy cycle and are annually reevaluated. Newer ver-
sions are implemented only when a significant improve-
ment over previous results can be demonstrated.
Potential pathogenicity of the variants (step 6) is eval-
uated by two senior scientists with extensive experience
in the analysis of exome data. All analyses are per-
formed independently and the results are then merged
for the presentation and debate at the GCTF (step 7).
Data pathogenicity estimation adheres to published
guidelines [9] that has allowed the standardization of
the process and has also guided a more structured ap-
proach towards the available databases (Table 1) that
are now used in order to support or reject specific
criteria. We are planning to set up a specific training
program in order to increase the number of people in-
volved and thus increase the capacity to perform exome
analysis for the patients.
Intermediate report and decisions on pathogenicity
(step 7 of Fig. 2)
The intermediate report, produced for each patient, in-
cludes a technical and a variant interpretation section.
The technical section documents all the HTS and bio-
informatics analysis aspects including the specific filter-
ing steps and quality metrics (e.g. genes, coverage, and
number of identified variants). For the interpretation
section we use the currently accepted 5 class variant
classification system (8) and several tools for the classi-
fication (Table 1) [8, 9].
All class 3, 4, and 5 variants [9] are documented in
the intermediate report with a summary of available lit-
erature and presented at the GCTF session (step 7).
The classification performed by the analysis team is de-
bated and occasionally the variants are reclassified after
thorough evaluation of potential phenotype-genotype
correlations. In cases where no clear pathogenic variant
is found, it is discussed whether further analyses are
warranted (e.g., MLPA for deletions/duplications, broader
bioinformatics analysis that includes analysis of additional
genes, Sanger sequencing of individual exons that are
insufficiently covered) or if familial segregation ana-
lysis of a variant is justified. If necessary, we extend
such segregation analysis up to second-degree relatives
(cousins, nephews/nieces) but this depends mainly on
disease status, demographic circumstances, and the in-
terfamilial relationships.
Verification, final report, and post-test considerations
(steps 8 and 9 in Fig. 2)
All identified variants (100 %) that are disclosed in the
final report are currently confirmed by Sanger sequen-
cing and the content of the final reports are discussed
during the GCTF sessions (step 8). All class 4 and 5 var-
iants identified in genes compatible with the phenotype
Table 1 Databases and tools routinely used for variant annotation
and classification. Additional databases and tools are used as
deemed necessary
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are reported. The disclosure of class 4 and 5 variants
considered as incidental findings is done according to
the patient’s pre-test decision. Class 3 variants are only
disclosed if they are found in a gene causing a phenotype
which is compatible with the clinical presentation of the
patient. In these cases, a remark that the variants should
be reevaluated in 1–2 years according to the evolving
knowledge is added.
Once the final report has been validated by the
GCTF, the report is signed by the senior molecular
biologist, allowing the clinical geneticists to subse-
quently arrange genetic counseling for communication
of the results (step 9).
Example illustrating the operating procedure of the GCTF
Dizygotic 12-month-old male twins were addressed for
genetic counseling because of seizures since the age of
4 months associated with severe developmental delay.
Family history was unremarkable. An array-CGH (reso-
lution 180 KB) was performed and identified a 417 kb
paternally inherited duplication at 6p12.2 that was con-
sidered non-pathogenic. Extensive paraclinical workup
and brain imaging did not reveal the cause. The clinical
geneticist in charge presented the situation at the
weekly GCTF meeting. Given the lack of diagnosis and
the severe presentation, we decided to perform WES
with targeted bioinformatics analysis of 120 selected
epilepsy genes. This initial analysis did not reveal any
potential pathogenic variants. It was then decided to
extend the analysis by including all known syndromic
and non-syndromic epilepsy genes. The second panel
consisted of 395 genes and revealed a novel missense
variant NM_020473.3:c.481G>A: p.(Glu161Lys) in the
gene PIGA on chromosome Xp22.2 (MIM 311770).
This variant concerns a very well-conserved nucleo-
tide (GERP: 5.89) and was predicted to be pathogenic
by all three bioinformatics tools (SIFT: 0, PolyPhen/
HumVar:0.931, Mutation Taster:0.999). Pathogenic muta-
tions in PIGA cause paroxysmal nocturnal hemoglobinuria
(MIM 300818) and multiple congenital anomalies-
hypotonia-seizures syndrome 2 (MCAHS2, MIM 300868).
The latter phenotypic description was concordant with the
children’s clinical presentation. The variant was transmit-
ted from their unaffected mother. No additional family
members were available for clinical testing. Based on the
aforementioned evidence, the variant was reported as
pathogenic. Our approach allowed us to expand the bio-
informatics analysis to additional genes without the need
for resequencing; however, the turnaround time was pro-
longed as we did not immediately include all potentially
causative genes. Based on this experience, and on similar
other situations, we decided to change our procedure and
to analyze directly the largest possible gene panel.
Reimbursement of HTS for Mendelian disorders
Another aim of the GCTF was to initiate together with
the Swiss Society of Medical Genetics the administrative
process with the Swiss Federal Office of Public Health
(SFOPH) in order to integrate HTS as a reimbursable
genetic test in the Swiss health care system. Genetic tests
in Switzerland are reimbursed according to a positive “list
of analyses” (LA) [17], which specifies each disorder and
testing method covered by the compulsory, albeit private,
medical insurance scheme. The LA includes an additional
nonspecific entry for orphan diseases, applicable to rare
Mendelian disorders, not otherwise registered in the LA.
In January 2015, after 30 months of continuous negotia-
tions with the Swiss Federal Office of Public Health, HTS
was officially introduced in the LA as a reimbursable gen-
etic test for Mendelian disorders [17]. In addition, the
Swiss Society of Medical Genetics (SSGM) [18] developed
a document of “good practice” for the use of HTS in clin-
ical setting [19], which was required by the SFOPH, covers
pre- and post-HTS genetic counseling issues, an informed
consent form adapted to HTS genetic testing, laboratory
requirements and specifications, regulations for secure
data storage and quality control, and disclosure of second-
ary findings and variants of unknown clinical significance,
as well as recommendations for the reporting of results.
The costs of HTS are based on the sum of three distinct
entries within the LA: laboratory costs of high-throughput
sequencing, bioinformatics analysis, and additional con-
firmatory laboratory analyses such as Sanger sequencing
and/or MLPA. More specifically:
1. High-throughput sequencing has a fixed price of
2300 CHF, irrespective of the sequencing technology
used (WES or targeted panel approach).
2. Bioinformatics analysis costs vary according to the
number of genes analyzed: 600 CHF for 1-10 genes,
1000 CHF for 11-100 genes and 1500 CHF for more
than 100 genes.
3. Confirmation of variants using Sanger sequencing
(215 CHF per variant): a maximum of two Sanger
confirmations for 1–10 genes, four for 11–100
genes, and six for more than 100 genes. In all cases,
a maximum of four multiplex ligation-dependent
amplification (MLPA) analyses can also be added to
the total cost (350 CHF per MPLA).
This modular setting enables flexibility for the diag-
nostic laboratories and allows each step to be per-
formed and charged separately. In particular, it allows
performing additional bioinformatics analyses without
resequencing, which is arguably cost-effective.
Additional requirements have been set forth by the
SFOPH for the reimbursement of HTS: diagnostic la-
boratories performing HTS must participate in quality
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assessment schemes (EQAs), according to the Swiss law
[20], and become accredited for HTS by the Swiss
Accreditation Service (SAS), before December 31, 2017.
Furthermore, all the steps of HTS need to be performed
within Switzerland. However, it is not necessary that
they are all performed within the same institution. Fi-
nally, because of the complexity of pre- and post-HTS
counseling, only board-certified medical geneticists [21]
are allowed to prescribe HTS tests of more than 10
genes. Physicians from all other medical specialties can
only prescribe HTS for less than 10 genes. In addition,
the requirements for expert genetic counseling are well
specified in the existing law for genetic analyses [22]. It
is planned to regularly update and reevaluate the re-
quirements from the SFOPH as well as the “good prac-
tice” document according to the new developments and
international recommendations in the field.
Experience to date
Until now we have designed 51 different gene lists
containing 2 to 1038 genes. On average, 160 (SD = 18)
million reads are produced per sample. After removal
of duplicate reads, 132 (SD = 22) million reads remain, 78
(SD = 8.5) million of which are on target (target = total
coding sequence as defined by RefSeq). These reads repre-
sent an average coverage of the coding portion of the
RefSeq genes of at least 20× for 94.73 % (±1.18 SD) and of
at least 30× for 92.08 % (±1.66 SD). On average, 21,565
(±1,125 SD) variants (SNVs and small indels) are detected
per individual.
So far, we enrolled 240 patients with our HTS ap-
proach. Thirty-two percent (77/240) displayed develop-
mental delay with or without other anomalies; the
remaining 68 % (163/240) presented with various hetero-
geneous Mendelian disorders such as short rib polydactyly
syndrome, juvenile Parkinson disease, connective tissue
disorders, Cornelia de Lange syndrome, microcephalic
primordial dwarfism (MPD), Kallmann syndrome, arthro-
gryposis, Gitelman syndrome, various inherited cardiac
diseases, Charcot-Marie-Tooth disease, Kabuki syndrome,
hereditary spastic paraparesis, or likely monogenic epi-
lepsy. We completed the final report for 139 of these
patients (47 with developmental delay and 92 with other
Mendelian disorders).
Pathogenic variants (class 4 or 5) were detected in
28 % (13/47) of the patients with developmental delay
(Fig. 3) and in 46 % (42/92) of the patients with other
Mendelian phenotypes (Fig. 4), which gives an average
detection rate of class 4 or 5 variants of 40 % (55/139)
(Table 2). Variants of unknown clinical significance
(VUS, class 3) were found in 23 % (11/47) of the patients
with developmental delay (Fig. 3) and in 10 % (9/92) of
the patients with other Mendelian phenotypes (Fig. 4).
So far, we reported 8 out of 20 identified VUS in the
final report.
Sanger sequencing of not well-covered exons in genes
that were considered to be highly compatible with the
phenotype was performed in two cases (2/139, 1.4 %)
and in one of them the causative variant was identified.
In six other cases (6/139, 4.3 %), bioinformatics analysis
of further added genes to the originally determined gene
panel resulted in the identification of the causative
variants.
Lessons learned
HTS has provided exciting new diagnostic opportun-
ities in the investigation of genetically heterogeneous
Mendelian disorders and has expanded the capacity to
test simultaneously a large number of candidate genes in a
timely fashion and for a reasonable cost. The advantages
of our approach include the following: (i) the use of one
common diagnostic test for all patients suffering from
Mendelian disorders with known pathogenic genes, (ii) it
is amenable to a customized and flexible bioinformatics
analysis, (iii) it allows us to invite all patients with a
Fig. 3 Results of targeted gene analysis in 47 patients with
developmental delay. Pathogenic variants were identified in 28 %,
VUS in 23 %, and no pathogenic variants were found in 49 % of the
patients, respectively
Fig. 4 Results of targeted gene analysis in 92 patients with various
Mendelian diseases. Pathogenic variants were found in 46 %, VUS
in 10 %, and no pathogenic variants were found in 45 % of the
patients, respectively
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Table 2 Causative variants identified in the resolved cases
Phenotype Gene panel Identified pathogenic variant(s)
1 Short rib polydactyly Short rib polydactyly panel (10 genes) NM_001377.2(DYNC2H1_v001):c.1953G>A:p.(=)
NM_001377.2(DYNC2H1_v001):c.4625 C>T:p.(Ala1542Val)
2 Severe ID ID (536 genes) NM_000489.4(ATRX_v001):c.6122G>A:p.(Ser2041Asn)
3 Intellectual disability, microcephaly ID (536 genes) NM_004380.2(CREBBP_v001):c.4665A>C:p.(Glu1555Asp)
4 Cornelia de Lange syndrome Cornelia de Lange panel (5 genes) NM_015384.4(NIPBL_v001):c.5483G>A:p.(Arg1828Gln)
5 Intellectual disability ID (536 genes) NM_004187.3(KDM5C_v001):c.769_770del
:p.(Leu257Alafs*5)
6 Glomerulopathy Glomerulopathy and Alport panel (61 genes) NM_000495.4(COL4A5_v001):c.2288G>A:p.(Gly763Glu)
7 Intellectual disability, psychotic
symptoms
ID (536 genes) NM_033517.1(SHANK3_v001):c.3637dup:p.(His1213Profs*83)
8 Microcephalic primordial dwarfism MPD panel (18 genes) NM_002312.3(LIG4_v001):c.2321T>C:p.(Leu774Pro)
NM_002312.3(LIG4_v001):c.2440C>T c.2440 C>T
p.(Arg814*)
9 Kallmann syndrome Kallmann panel (21 genes) NM_015850.3(FGFR1_v001):c.1444del:p.(Leu482Trpfs*25)
10 Dyskinesia, dystonia, myoclonia Dystonia panel (8 genes) NM_003919.2(SGCE_v001):c.783dup :p.(Phe262Ilefs*8)
11 Cardiac arrest Cardiomyopathy panel (66 genes) NM_001035.2(RYR2_v001):c.14711G>A:p.(Gly4904Asp)
12 Periodic fever syndrome Periodic fever panel (4 genes) NM_004895.4(NLRP3_v001):c.1049C>T:p.(Thr350Met)
13 Intellectual disability, microcephaly,
strabismus
ID (536 genes) NM_021140.3(KDM6A_v001):c.3598C>T :p.(Leu1200Phe)
14 Hereditary spastic paraplegia Hereditary spastic paraplegia panel (45 genes) NM_014846.3(KIAA0196_v001):c.1857G>C:p.(Leu619Phe)
15 Epileptic encephalopathy Epilepsy panel (395 genes) NM_020473.3(PIGA_v001):c.481G>A:p.(Glu161Lys)
16 Gitelman syndrome Gitelman syndrome panel (2 genes) NM_000339.2(SLC12A3_v001):c.1924C>G:p.(Arg642Gly)
17 Autism, Intellectual disability,
trigonocephaly
ID (536 genes) NM_001111125.2(IQSEC2_v001):c.2477T>C:p.(Met826Thr)
18 Aortic dissection Aneurysm panel (20 genes) NM_000138.4(FBN1_v001):c.6616G>A:p.(Asp2206Asn)
19 Epileptic encephalopathy Epileptic encephalopathy (141 genes) NM_004518.4(KCNQ2_v001):c.821C>T :p.(Thr274Met)
20 Kabuki syndrome Kabuki panel (2 genes) NM_003482.3(KMT2D_v001):c.12661C>T:p.(Gln4221*)
21 Hereditary Spastic paraparesis Spastic paraparesis panel (11 genes) NM_199436.1(SPAST_v001):c.1015C>T :p. (Leu339Phe)
22 Ohdo syndrome KAT6B gene NM_001256468.1(KAT6B_v001):c.4652_4661dup:
p.(Gln1554Hisfs*41)
23 Neurofibramotosis type 1 NF panel (2 genes) NM_000267.3 (NF1_v001):c1381C>T: p.(Arg461*)
24 Inclusion body myositis Inclusion body myosotis panel (10 genes) NM_001927.3 (DES_v001):c.1155G>T:p.(Asp399Tyr)
25 Noonan syndrome Noonan and rasopathy syndrome (12 genes) NM_002834.3 (PTPN11_v001):c.797G>C:p.(Glu139Asp)
26 Periodic fever Personalized periodic fever panel (207 genes) NM_000243.2 (MEFV_v001):c.2084A>G:p.(Lys695Arg)
27 Charcot Marie Tooth type 2 CMT2 panel (23 genes) NM_001005373.3 (LRSAM1_v001):c.2069T>C:p.(Cys690Arg)
28 Hypoglycemia on congenital
hyperinsulinemia
Congenital hyperinsulinemia panel (10 genes) NM_000525.3 (KCNJ11_v001):c.400T>C:p.(Leu147Pro)
NM_000525.3 (KCNJ11_v001):c.154C>T:p.(Gln52*)
29 Cardiomyopathy Cardiomyopathy panel (66 genes) NM_001018008.1 (TPM1_v001):c.304G>A:p.(Glu102Lys)
30 Intellectual disability, epilepsy Intellectual disability panel (537 genes) NM_000834.3 (GRIN2B_v001):c.1598G>A:p.(Gly533Asp)
31 X-linked intellectual disability Intellectual disability panel (990 genes) NM_003916.4 (AP1S2_v001):c.1-3C>A
32 Lissencephaly Lissencephaly panel (12 genes) NM_000403.3 (PAFAH1B1_v001):c.162dupA:p.(Trp55Metfs*6)
33 Vascular leukoencephalopathy Vascular leukoencephalopathy panel (7 genes) NM_002775.4 (HTRA1_v001):c.854C>T:p.(Pro285Leu)
34 Cardiomyopathy Cardiomyopathy panel (66 genes) NM_000256.3 (MYBPC3_v001):c.3324-3325del:p.
(Lys1108Asnfs*41)
35 Cardiomyopathy Cardiomyopathy panel (66 genes) NM_000256.3 (MYBPC3_v001):c.3697C>T:p.(Gln1233*)
36 Cardiomyopathy and connective
tissue disorder
Cardiomyopathy and connective tissue disorder
panel (166 genes)
NM_0004415.2 (DSP_v001):c.4003C>T:p.(Gln1335*)
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negative result to contact us again within an interval
of 1–2 years, in order to reevaluate the results and
possibly expand the analysis according to new discov-
eries without the need to re-sequence, (iv) it mini-
mizes the probability of incidental findings not related
to the patient’s disease.
However, WES followed by targeted bioinformatics
also has drawbacks. Firstly, from the sequencing
depth and coverage point of view, the capture pro-
cedure of the whole exome is less efficient when com-
pared to well-established targeted gene panel enrichment.
Nevertheless, with the use of the most recently marketed
whole exome capture reagents, this is gradually becoming
less of an issue [23], although there is a need to continu-
ously monitor the coverage. This drawback may be par-
tially resolved by filling up the sequencing gaps using
traditional methods such as targeted Sanger sequencing of
poorly covered exons. This complementary procedure was
recently introduced in the proposed draft of the Eurogent-
est guidelines for next-generation sequencing [24].
The second difficulty concerns the selection of genes
of interest, which is not yet standardized, and thus re-
mains idiosyncratic and to some extent subjective.
Although our approach allows a very flexible and liberal
selection of genes, a human omission or a change in
the gene name increases the risk of false negative re-
sults. Furthermore, the possibility exists to include, par-
ticularly in large gene lists such as the one for
intellectual disability, some actionable genes with broad
phenotypic spectrum of manifestations or not directly
linked to the investigated phenotype. Our experience
has shown that it is crucial to regularly reevaluate the
gene lists, ideally by two independent individuals using
criteria adapted for diagnostic testing, such as the level
of evidence for pathogenicity and its correlation with a
known phenotype. Yet, despite rigorous monitoring of
the literature, the risk of wrongful inclusion or exclu-
sion of genes remains. We strongly encourage the es-
tablishment of international norms and criteria for
selecting gene panels, in order to render the diagnostic
possibilities universal. For example, achievements such
as the release of the Eurogentest guidelines are a wel-
come development [25].
We do not routinely perform trio sequencing (father,
mother, affected offspring) despite the fact that the trio
approach seems to have a slightly higher diagnostic yield
Table 2 Causative variants identified in the resolved cases (Continued)
37 Intellectual disability Intellectual disability panel (990 genes) NM_002834.3 (PTPN11_v001):c.794G>A:p.(Arg265Gln)
38 Cystinuria Cystinuria panel (2 genes) NM_001243036 (SLC7A9_v001):c.1225-4678_1324del
39 Noonan syndrome Noonan panel (12 genes) NM_002834.3 (PTPN11_v001):c.923A>G:p.(Asn308Ser)
40 Intellectual disability, microcephaly Personalized panel (2 genes: DYRK1A
and DDX3X)
NM_00139.3 (DYRK1A_v001):c.1491delC:p.(Ala498Profs*94)
41 Neonatal encephalopathy Encephalopathy panel (225 genes) NM_001909.4 (CTSD_v001):c.686_688del:p.(Phe229del)
42 Intellectual disability, cryptorchidism Intellectual disability panel (990 genes) NM_001243234.1 (TCF4_v001):c.656dupT:p.(Leu219Phefs*9)
43 Intellectual disability, obesity Intellectual disability panel (990 genes) NM_032531.3 (KIRREL3_v001):c.2019G>A:p.(Met673Ile)
44 Epilepsy, vertigo, episodic ataxia Epilepsy (396 genes) NM_0010540143.1 (SCN2A_v001):c.2960G>T:p.(Ser987Ile)
45 Intellectual disability Intellectual disability panel (990 genes) NM_015559.2 (SETBP1_v001):c.2016-2017insT:p.(Lys673*)
46 Kabuki syndrome Kabuki panel (2 genes) NM_003482.3 (KMT2D_v001):c.2994delT:p(Met999*)
47 Long QT syndrome Arythmia panel (47 genes) NM_000238.3 (KCNH2_v001):c.1786C>G:p(Pro596Ala)
48 Rubinstein-Taybi syndrome Rubinstein-Taybi syndrome panel (2 genes). NM_004380.2 (CREBBP_v001). Variant found by MLPA
49 Aneurysm and dyslipidemia Aneurysm and dyslipidemia panel (50 genes) NM_000041.3 (APOE_v001):c.461G>T:p.(Arg154Leu)
50 Marfan syndrome Marfan syndrome panel (8 genes) NM_000138.4 (FBN1_v001):c.7339G>A:p.(Glu2447Lys)
51 Ehlers-Danlos syndrome Ehlers-Danlos panel (4 genes) NM_000093.4 (COL5A1_v001):c.2203dupC:p.
(Gln735Profs*25)
52 Epileptic encephalopathy and
intellectual disability
Intellectual disability and epilepsy panel
(1038 genes)
NM_001127648.1 (GABRA1_v001):c.641G>A:p.(Arg214His)
53 Intellectual and communication
disability




Cardiomyopathy panel (66 genes) NM_001018008.1 (TPM1_v001):c.304G>A:p.(Glu102Lys)
55 Dilated non compaction
cardiomyopathy
Arythmia and cardiomyopathy panel (97 genes) NM_003319.4 (TTN_v001):c.49905dup:p.(Pro16636Thrfs*9)
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[26]. The main reasons for this decision are financial, as
the health insurances only reimburse the HTS costs of
the proband but not that of the parents.
The most demanding challenge in clinical HTS arguably
remains the issue of variant interpretation. Since the num-
ber of variants identified is roughly proportional to the
number of analyzed genes, the task of variant interpret-
ation rises accordingly. In our group, each variant’s patho-
genicity is first assessed by the analysis team according to
international guidelines [9] and then presented, discussed,
and evaluated for concordance with the phenotype of the
patient during the GCTF sessions. The input of expert
physicians familiar with the patient’s phenotype is
invaluable as well as the interpretation workup and
knowhow of the laboratory team. The emerging data-
bases for the pathogenicity of variants are also ex-
tremely important, and sharing of the interpretation of
variants among diagnostic centers is crucial. Clinical
knowledge and experience help to (mostly) exclude var-
iants as non-relevant to the phenotype or to consider
them as likely pathogenic [9, 10]. This complementary
exchange is in our opinion indispensable for adequate
variant interpretation, especially in cases of large gene
lists with several potentially pathogenic variants identi-
fied. Accordingly, in a few cases, the consensus of
GCTF was to consider the identified variant as likely
pathogenic (class 4), despite VUS classification (class 3)
by the analysis team according to the guidelines [9].
In order to further facilitate and improve variant
interpretation, the need for international sharing of
variants and phenotypes is of paramount importance
and cannot be overemphasized. We have put in place a
semi-automatic submission of variants of classes 3/4/5
in ClinVar. Furthermore, false positive “pathogenic”
variants that have been misclassified in the past need to
be updated in relevant databases, so that false diagnoses
will not be perpetuated.
In parallel to the technical advances, ethical aspects
have to be constantly considered at the present stage of
HTS genetic testing. One important issue concerns the
pre- and post-HTS genetic counseling challenges, in-
cluding informed consent. The expert participation of
ethicists within the GCTF was of considerable value for
the development of a specific informed consent form for
HTS application in accordance with the Swiss law on
genetic testing [22] and also for the continuous reevalua-
tion of our procedures. The informed consent form re-
spects the rights to know and not to know, especially
concerning secondary findings in actionable genes and
carrier status for recessive disorders. Our experience to
date has shown that the majority of patients and parents
want to know about treatable diseases or diseases for
which effective preventive measures exist, but decide not
to know about non-treatable disorders and carrier status.
Additionally, almost all have agreed that their DNA and
sequencing data could be stored for prospective future
research projects. All these aspects need to be systemat-
ically studied on large cohorts in order to provide statis-
tically meaningful conclusions.
A further key effort of the GCTF together with the
Swiss Society of Medical Genetics was regarding the re-
imbursement of HTS as a diagnostic test by the insur-
ance companies. It necessitated 2.5 years of continuous
negotiations with the SFOPH until the proposal for for-
mal reimbursement was accepted by the federal health
authorities. To our knowledge, Switzerland is the first
European country for which a specific formal policy for
reimbursing of HTS for Mendelian disorders has been
introduced. In a few European countries, reimbursement
is achieved through general genetic testing policies;
while in most other countries, HTS is still being funded
by research projects or by non-reimbursable payments
from the consumers. We hope that reimbursement
policies will be developed in other countries in order to
achieve a widespread acceptance and use of HTS for the
diagnosis of genetic disorders.
In conclusion, the multidisciplinary GCTF has
allowed us to implement a number of local proce-
dures and criteria necessary to ensure high standard
clinical services within the new field of diagnostic
HTS, as well as to achieve in collaboration with the
Swiss Society of Medical Genetics the formal federal deci-
sion for HTS reimbursement for monogenic disorders.
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